Iradimed Corp: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 6, 2020 and accepted by EDGAR at Nov 6, 2020, 07:00 ET.
Management's discussion and analysis
As filed, 28,628 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis should be read in conjunction with our condensed financial statements and the related notes to those statements included in this Quarterly Report, the discussion of certain risks and uncertainties contained in Part II, Item 1A of this Quarterly Report, the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business” included in our Annual Report filed on Form 10-K for the fiscal year ended December 31, 2019 and the cautionary information regarding forward-looking statements at the beginning of this Quarterly Report.
Our Business
We develop, manufacture, market and distribute Magnetic Resonance Imaging (“MRI”) compatible medical devices and accessories and services relating to them.
We are a leader in the development of innovative MRI compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Each IV infusion pump system consists of an MRidium® MRI compatible IV infusion pump, non-magnetic mobile stand, proprietary disposable IV tubing sets and many of these systems contain additional optional upgrade accessories.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
We generate revenue from the sale of MRI compatible medical devices and accessories, extended warranty agreements, services related to maintaining our products and the sale of disposable products used with our devices. The principal customers for our MRI compatible products include hospitals and acute care facilities, both in the U.S. and internationally.
Selling cycles for our devices have varied widely and have historically ranged between three and six months in duration with more recent trends lengthening beyond this historical range due to the COVID-19 pandemic. We also enter into agreements with healthcare supply contracting companies in the U.S., which enable us to sell and distribute our products to their member hospitals. Under these agreements, we are required to pay these group purchasing organizations (“GPOs”) a fee of three percent of the sales of our products to their member hospitals. Our current GPO contracts effectively give us the ability to sell to more than 95 percent of all U.S. hospitals and acute care facilities.
Financial Highlights
Our revenue decreased $(2.3) million, or (22.7) percent, to $7.7 million for the third quarter ended September 30, 2020, compared to $10.0 million for the third quarter last year. Net income was $1.1 million, or $0.09 per diluted share in the third quarter ended September 30, 2020, compared to net income of $2.5 million, or $0.20 per diluted share in the third quarter last year.
COVID-19 Impact
In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic, which continues to spread throughout the U.S. and the world and has resulted in authorities implementing numerous measures to contain the virus, including travel bans and restrictions, quarantines, shelter-in-place orders, business limitations and shutdowns. Subsequent relaxations of these measures have been locally irregular and unpredictable and, in some jurisdictions, been reimposed based on reported incidence rates. While we are unable to accurately predict the full impact that COVID-19 will have on our results from operations, financial condition, liquidity and cash flows due to numerous uncertainties, including the duration and severity of the pandemic and containment measures, our compliance with these changing measures has impacted our day-to-day operations and could disrupt our business and operations, as well as that of our customers and suppliers, for an indefinite period of time. Considering the significant uncertainties created by COVID-19, we withdrew our 2020 financial guidance on April 7, 2020.
We have taken several steps to support the health and well-being of our employees as a result of the pandemic, including implementing more stringent cleaning procedures at our headquarters and manufacturing facility and, adopting a policy allowing all employees to donate their accrued time off to other employees unable to work due to COVID-19 issues.
The COVID-19 pandemic has resulted in significant economic disruption across the globe and has and will likely continue to adversely affect our business. Many of our hospital customers have and will likely continue to restrict access to healthcare workers only, diminishing our ability to generate sales, which has resulted in declining revenue during 2020 and may delay the timing of future orders. Resulting from hospitals restricting access to their facilities, we made certain investments in equipment to facilitate virtual meetings to enhance our selling process and perform product demonstrations and training.
Our business may also be adversely impacted as a result of the pandemic’s global economic impact. For example, hospitals may curtail their overall capital spending, or we may be unable to collect receivables from customers significantly impacted by COVID-19. Also, a decrease in orders in a given period could negatively affect our revenues in future periods from sales of our disposables and extended maintenance contracts, particularly if experienced on a sustained basis.
We believe that our current cash, investments and any cash generated from operations will be sufficient to meet our ongoing operating requirements for at least the next 12 months. We do not anticipate requiring additional capital; however, if required or desirable, we may seek to obtain a credit facility, raise debt or issue additional equity in private or public markets.
We continue to monitor the situation and may take further actions altering our business operations that we determine are in the best interest of our employees, customers, partners, suppliers, and stockholders, or as required by federal, state, or local authorities.
Application of Critical Accounting Policies
We prepare our financial statements in conformity with GAAP. The preparation of these financial statements requires us to make estimates and use assumptions that affect the reported amounts of assets, liabilities and related disclosures at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
We believe that the following critical accounting policies require the use of significant estimates, assumptions, and judgments:
- Revenue recognition;
- Accounts receivable and allowance for doubtful accounts;
- Inventory carried at the lower of cost or net realizable value;
- Stock-based compensation; and
- Income taxes.
These critical accounting policies are described in more detail in our Annual Report filed on Form 10-K, under Management’s Discussion and Analysis and Results of Operations. Except as disclosed in Note 1 to the unaudited condensed financial statements contained herein related to the adoption of recent accounting pronouncements, there have been no changes to these policies during the three and nine months ended September 30, 2020.
The use of different estimates, assumptions, and judgments could have a material effect on the reported amounts of assets, liabilities and related disclosures as of the date of the financial statements and revenue and expenses during the reporting period.
Results of Operations
The following table sets forth selected statements of operations data as a percentage of total revenue for the periods indicated. Our historical operating results are not necessarily indicative of the results for any future period.
| | Percent of Revenue Three Months Ended September 30, 2020 | 2019 | Percent of Revenue Nine Months Ended September 30, 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of revenue | 25.4 | 21.8 | 26.1 | 22.0 |
| Gross profit | 74.6 | 78.2 | 73.9 | 78.0 |
| Operating expenses: | | | | |
| General and administrative | 28.5 | 26.2 | 43.4 | 27.1 |
| Sales and marketing | 29.6 | 23.1 | 30.6 | 23.9 |
| Research and development | 6.2 | 3.7 | 6.0 | 3.8 |
| Total operating expenses | 64.4 | 53.0 | 80.0 | 54.8 |
| Income (loss) from operations | 10.2 | 25.3 | (6.1) | 23.2 |
| Other income, net | 0.1 | 1.1 | 0.5 | 1.0 |
| Income (loss) before provision for income taxes | 10.3 | 26.4 | (5.5) | 24.2 |
| Provision for income tax (benefit) expense | (3.6) | 1.7 | (8.7) | 1.1 |
| Net income | 14.0% | 24.6% | 3.2% | 23.1% |
Revenue by Geographic Region
| | | Three Months Ended September 30, 2020 | | 2019 | | Change | Nine Months Ended September 30, 2020 | | 2019 | | Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | | $6,465,184 | | $8,281,854 | | (21.9)% | $17,430,206 | | $22,916,642 | | (23.9)% |
| International | 1,233,912 | 1,681,445 | (26.6)% | 5,741,123 | 4,709,846 | 21.9% | |||||
| Total Revenue | | $7,699,096 | | $9,963,299 | | (22.7)% | $23,171,329 | | $27,626,488 | | (16.1)% |
Revenue by Type
| Devices: | | Three Months Ended September 30, 2020 | | 2019 | | Change | | Nine Months Ended September 30, 2020 | | 2019 | Change | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRI Compatible IV Infusion Pump Systems | | $2,153,699 | | $4,769,252 | | (54.8)% | | $6,693,692 | | $13,512,548 | (50.5)% | |
| MRI Compatible Patient Vital Signs Monitoring Systems | | 2,282,943 | | 2,557,889 | | (10.7)% | | 6,829,932 | | 6,215,528 | 9.9% | |
| Total Devices revenue | | 4,436,642 | | 7,327,141 | | (39.4)% | | 13,523,624 | | 19,728,076 | (31.4)% | |
| Disposables, service and other | | 2,802,039 | | 2,162,602 | | 29.6% | | 8,269,487 | | 6,513,030 | 27.0% | |
| Amortization of extended warranty agreements | | 460,415 | | 473,556 | | (2.8)% | | 1,378,218 | | 1,385,382 | (0.5)% | |
| Total revenue | | $7,699,096 | | $9,963,299 | | (22.7)% | | $23,171,329 | | $27,626,488 | (16.1)% | |
For the three months ended September 30, 2020, revenue decreased $(2.3) million, or (22.7) percent, to $7.7 million from $10.0 million for the same period in 2019.
Revenue from sales in the U.S. decreased $(1.8) million, or (21.9) percent, to $6.5 million for the third quarter 2020, from $8.3 million for the third quarter 2019. Revenue from sales internationally decreased $(0.5) million, or (26.6) percent, to $1.2 million for the third quarter 2020, from $1.7 million for the third quarter 2019. Domestic sales accounted for 84.0 percent of revenue for the third quarter 2020, compared to 83.1 percent for the third quarter 2019.
Revenue from sales of devices decreased $(2.9) million, or (39.4) percent, to $4.4 million for the three months ended September 30, 2020, from $7.3 million for the same period in 2019.
The average selling price of our MRI compatible IV infusion pump system during the three months ended September 30, 2020 was approximately $37,800, compared to approximately $35,100 for the same period in 2019. The increase in ASP relates to a favorable product sales mix when compared to the same period in 2019.
The average selling price of our MRI compatible patient vital signs monitoring system during the three months ended September 30, 2020 was approximately $43,000, compared to approximately $33,700 for the same period in 2019. The increase in ASP relates to a favorable product sale mix and higher domestic sales of our MRI compatible patient vital signs monitoring system recognized in revenue when compared to the same period in 2019.
Revenue from sales of our disposables, service and other increased $0.6 million, or 29.6 percent, to $2.8 million for the three months ended September 30, 2020, from $2.2 million for the same period in 2019. Revenue from the amortization of extended maintenance contracts was consistent at $0.5 million for the three months ended September 30, 2020 and 2019.
For the nine months ended September 30, 2020, revenue decreased $(4.4) million, or (16.1) percent, to $23.2 million from $27.6 million for the same period in 2019.
Revenue from sales in the U.S. decreased $(5.5) million, or (23.9) percent, to $17.4 million for the nine months ended September 30, 2020, from $22.9 million for the same period in 2019. Revenue from sales internationally increased $1.0 million, or 21.9 percent, to $5.7 million for the nine months ended September 30, 2020, from $4.7 million for the same period in 2019. Domestic sales accounted for 75.2 percent of revenue for the nine months ended September 30, 2020, compared to 83.0 percent for the same period 2019.
Revenue from sales of devices decreased $(6.2) million, or (31.4) percent, to $13.5 million for the nine months ended September 30, 2020, from $19.7 million for the same period in 2019.
The average selling price of our MRI compatible IV infusion pump system during the nine months ended September 30, 2020 was approximately $32,200, compared to approximately $35,400 for the same period in 2019. The decrease in ASP relates to higher international sales of our MRI compatible IV infusion pump recognized in revenue when compared to the same period in 2019.
The average selling price of our MRI compatible patient vital signs monitoring system during the nine months ended September 30, 2020 was approximately $35,800, compared to approximately $32,800 for the same period in 2019. The increase in ASP relates to a favorable product sales mix, partially offset by higher international sales of our 3880 MRI compatible patient vital signs monitoring system recognized in revenue when compared to the same period in 2019.
Revenue from sales of our disposables, service and other increased $1.8 million, or 27.0 percent, to $8.3 million from $6.5 million for the same period in 2019. Revenue from the amortization of extended maintenance contracts was consistent at $1.4 million for the nine months ended September 30, 2020 and 2019.
Cost of Revenue and Gross Profit
| | | Three Months Ended September 30, 2020 | 2019 | | Nine Months Ended September 30, 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | | $7,699,096 | $9,963,299 | | $23,171,329 | $27,626,488 | |
| Cost of revenue | | 1,958,036 | 2,168,208 | | 6,036,353 | 6,074,323 | |
| Gross profit | | $5,741,060 | $7,795,091 | | $17,134,976 | $21,552,165 | |
| Gross profit percentage | | 74.6% | 78.2% | | 73.9% | 78.0% | |
For the three months ended September 30, 2020, cost of revenue decreased $(0.2) million, or (9.7) percent, to $2.0 million from $2.2 million for the same period in 2019. Gross profit decreased $(2.1) million, or (26.4) percent, to $5.7 million for the third quarter 2020 from $7.8 million for the same period in 2019. The decrease in gross profit is primarily due to lower revenue and unfavorable overhead variances.
Gross profit margin was 74.6 percent for third quarter 2020, compared to 78.2 percent for the third quarter 2019. The decrease in gross profit margin is due to unfavorable overhead variances.
For the nine months ended September 30, 2020, cost of revenue decreased $(0.1) million, or (0.6) percent, to $6.0 million from $6.1 million for the same period in 2019. Gross profit decreased $(4.5) million, or (20.5) percent, to $17.1 million for the nine months ended September 30, 2020 from $21.6 million for the same period in 2019. The decrease in cost of revenue and gross profit is primarily due to lower revenue and unfavorable overhead variances, partially offset by favorable inventory cost variances.
Gross profit margin was 73.9 percent for the nine months ended September 30, 2020, compared to 78.0 percent for the same period in 2019. The decrease in gross profit margin is due to higher international revenue as a percent of total revenue and unfavorable overhead variances, partially offset by favorable inventory cost variances.
Operating Expenses
| | | Three Months Ended September 30, 2020 | 2019 | | Nine Months Ended September 30, 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| General and administrative | | $2,196,935 | $2,609,722 | | $10,062,089 | $7,482,790 | |
| Percentage of revenue | | 28.5% | 26.2% | | 43.4% | 27.1% | |
| Sales and marketing | | $2,282,491 | $2,297,002 | | $7,090,192 | $6,607,477 | |
| Percentage of revenue | | 29.6% | 23.1% | | 30.6% | 23.9% | |
| Research and development | | $476,876 | $369,526 | | $1,389,812 | $1,053,409 | |
| Percentage of revenue | | 6.2% | 3.7% | | 6.0% | 3.8% | |
General and Administrative
For the three months ended September 30, 2020, general and administrative expense decreased $(0.4) million, or (15.8) percent, to $2.2 million from $2.6 million for the same period last year. This decrease is primarily due to lower expenses from employee bonuses, legal and professional expenses and regulatory expenses.
For the nine months ended September 30, 2020, general and administrative expense increased $2.6 million, or 34.5 percent, to $10.1 million from $7.5 million for the same period last year. This increase is primarily due to higher expenses from stock and cash compensation related to the separation of our former Chief Executive Officer, higher payroll and benefits costs related to higher headcount, partially offset by lower legal and professional expenses. During the nine months ended September 30, 2020, the Company recognized total general and administrative expense of $3.2 million related to our former Chief Executive Officer, of which $2.7 million relates to the separation.
Sales and Marketing
For the three months ended September 30, 2020 and 2019, sales and marketing expense was consistent at $2.3 million. For the three months ended September 30, 2020, sales and marketing expense was 29.6 percent of revenue compared to 23.1 percent for the same period in 2019. This is primarily the result of higher payroll and employee benefits costs higher sales commissions expense, offset by lower sales activities expenses.
For the nine months ended September 30, 2020, sales and marketing expense increased $0.5 million, or 7.3 percent, to $7.1 million from $6.6 million for the same period last year. This increase is primarily the result of higher payroll and employee benefits costs and higher sales commissions, partially offset by lower sales activities expenses.
Research and Development
For the three months ended September 30, 2020, research and development expense increased $0.1 million, or 29.1 percent, to $0.5 million from $0.4 million for the same period last year. This increase is primarily the result of higher payroll and employee benefits costs due to increased headcount, partially offset by lower consulting expenses.
For the nine months ended September 30, 2020 and 2019, research and development expense increased $0.3 million, or 31.9 percent, to $1.4 million from $1.1 million for the same period last year. This increase is primarily the result of higher payroll and employee benefits expenses due to increased headcount and higher employee recruiting expenses, partially offset by lower consulting expenses.
Other Income, Net
Other income, net consists of interest income, foreign currency gains and losses, and other miscellaneous income. For the three months ended September 30, 2020 and 2019, we reported other income of approximately $9,000 and $110,000, respectively. This decrease is primarily due to lower interest income.
For the nine months ended September 30, 2020 and 2019, we reported other income of approximately $126,000 and $281,000, respectively. This decrease is primarily due to lower interest income.
Income Taxes
For the three and nine months ended September 30, 2020, we recorded a provision for income tax benefit of $(0.3) million and $(2.0) million, respectively. Our effective tax rate was (35.3) percent and 157.1 percent, respectively, and differed from the U.S. Federal statutory rate primarily due to discrete items related to tax benefits associated with stock-based compensation and a U.S. state tax benefit, partially offset by a limitation on the deductibility of certain executive compensation associated with the separation of our former Chief Executive Officer. Additionally, we recognized a benefit in our effective tax rate resulting from the Coronavirus Aid, Relief, and Economic Security Act, which allowed us to carryback net operating losses to years prior to the enactment of the Tax Cuts and Jobs Act.
For the three and nine months ended September 30, 2019, we recorded a provision for income tax expense of $0.2 million and $0.3 million, respectively. Our effective tax rate was 6.6 percent and 4.5 percent, respectively, and differed from the U.S. Federal statutory rate primarily due to discrete items related to tax benefits associated with stock-based compensation and the foreign derived intangible income deduction, partially offset by U.S. state tax expense.
As of September 30, 2020, and December 31, 2019, we had not identified or accrued for any uncertain tax positions. We are currently unaware of any uncertain tax positions that could result in significant payments, accruals or other material deviations in this estimate over the next 12 months. We believe that our tax positions comply in all material respects with applicable tax law. However, tax law is subject to interpretation, and interpretations by taxing authorities could be different from ours, which could result in the imposition of additional taxes and penalties.
We file tax returns in the U.S. Federal jurisdiction and many U.S. state jurisdictions. The Company is subject to income tax examinations for our U.S. Federal and certain U.S. state income taxes for 2016 and subsequent years and various other U.S. state income taxes for 2015 and subsequent years.
Liquidity and Capital Resources
Our principal sources of liquidity have historically been our cash and cash equivalents balances, our investments, cash flow from operations and access to the financial markets. Our principal uses of cash are operating expenses, working capital requirements and capital expenditures.
As of September 30, 2020, we had cash and investments of $49.9 million, stockholders’ equity of $60.7 million, and working capital of $58.1 million. As of December 31, 2019, we had cash and investments of $46.3 million, stockholders’ equity of $55.5 million, and working capital of $53.1 million.
We believe that our current cash, investments and any cash generated from operations will be sufficient to meet our ongoing operating requirements for at least the next 12 months. We do not anticipate requiring additional capital; however, if required or desirable, we may seek to obtain a credit facility, raise debt or issue additional equity in private or public markets.
| | | Nine Months Ended September 30, 2020 | | 2019 | |
|---|---|---|---|---|---|
| Net cash provided by operating activities | | $3,321,428 | | $6,283,874 | |
| Net cash (used in) provided by investing activities | | (53,564) | | 2,265,719 | |
| Net cash provided by financing activities | | 799,974 | | 2,060,127 | |
Cash provided by operating activities decreased $(3.0) million to $3.3 million for the nine months ended September 30, 2020, compared to $6.3 million for the same period in 2019. During the nine months ended September 30, 2020, cash provided by operations was positively impacted by cash inflows from accounts receivable and deferred revenue, and negatively impacted by prepaid income taxes, inventory, prepaid expenses and other current assets, accrued payroll and benefits, other accrued taxes and accounts payable.
Cash used in investing activities decreased $(2.4) million to $(0.1) million for the nine months ended September 30, 2020, compared to cash provided by investing activities of $2.3 million for the same period in 2019. This decrease is primarily due to proceeds from the maturity of investments.
Cash provided by financing activities decreased $(1.3) million to $0.8 million for the nine months ended September 30, 2020, compared to $2.1 million for the same period in 2019. This decrease is due to higher taxes paid for the net share settlement of restricted stock units and lower proceeds from the exercise of stock options.
We market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses.
Our manufacturing and headquarters facility has been leased from Susi, LLC, an entity controlled by our Chairman of the Board and Chief Executive Officer, Roger Susi. Pursuant to the terms of our lease, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index.
Off-Balance Sheet Arrangements
As of September 30, 2020 and December 31, 2019, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Contractual Obligations
There have been no material changes outside the ordinary course of business to our contractual obligations and commercial commitments since December 31, 2019.
Recent Accounting Pronouncements
See Note 1 to the unaudited condensed financial statements contained herein for a full description of recent accounting pronouncements including the respective expected dates of adoption and status of evaluation of expected effects on results of our operations and financial condition.
Market risk
As filed, 2,166 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Foreign Currency Exchange Risk
We have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. Dollar, principally the Japanese yen (“Yen”). The volatility of the Yen depends on many factors that we cannot forecast with reliable accuracy. We have experienced and will continue to experience fluctuations in our net income because of transaction gains (losses) related to revaluing Yen denominated accounts payable balances. In the event our Yen denominated accounts payable or expenses increase, our operating results may be affected by fluctuations in the Yen exchange rate. If the U.S. Dollar uniformly increased or decreased in strength by 10 percent relative to the Yen, our net income would have correspondingly increased or decreased by an immaterial amount for the three and nine months ended September 30, 2020 and 2019.
Interest Rate Risk
When able, we invest excess cash in bank money-market funds, corporate debt securities or discrete short-term investments. The fair value of our cash equivalents and short-term investments is sensitive to changes in the general level of interest rates in the U.S., and the fair value of these investments will decline if market interest rates increase. As of September 30, 2020, we had $2.3 million in corporate bonds, with $1.4 million maturing in less than 1 year and $0.9 million maturing between 1 and 3 years. These corporate bonds have fixed interest rates and semi-annual interest payment dates. If market interest rates were to change by 100 basis points from levels at September 30, 2020, we expect the corresponding change in fair value of our investments would be approximately $21,000. This is based on sensitivity analyses performed on our financial position as of September 30, 2020. Actual results may differ as our analysis of the effects of changes in interest rates does not account for, among other things, sales of securities prior to maturity and repurchase of replacement securities, the change in mix or quality of the investments in the portfolio, and changes in the relationship between short-term and long-term interest rates.
Controls and procedures
As filed, 2,130 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 3,602 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In evaluating the Company and its business, you should carefully consider the information included in this Quarterly Report on Form 10-Q and the factors discussed under Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as well as in other documents we file with the SEC. Except as described below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
Our business, financial condition and operations may be materially adversely affected by the COVID-19 pandemic or other public health crises.
The COVID-19 pandemic, and the resulting restrictions intended to slow the spread of COVID-19, including stay-at-home orders, business shut downs and other restrictions, has and will likely continue to adversely affect our business in a number of ways. To respond to the demands of managing COVID-19 and the resulting economic uncertainties, healthcare organizations may be forced to adjust spending priorities by increased spending related to COVID-19, which may have a significant effect on the demand and available budget for our products and related services. The financial strains on healthcare systems may also lead to an increased risk of delays in customer payments. In addition, a recession resulting from the spread of COVID-19 could materially affect our business, especially if a recession results in higher unemployment causing potential patients to not have access to health insurance. Our ability to generate sales may be further disrupted by hospitals restricting access to hospital workers only. A decline in operating results has limited and could further limit our generation of capital resources and cause financial stress if we are unable to increase revenues or adjust our costs appropriately to changes in revenue. We believe that COVID-19’s adverse impact on our operating results, cash flows and financial condition will be primarily driven by the severity and duration of the pandemic and its impact on the U.S. and global economy.
In addition to adversely impacting demand for our products, COVID-19 or other public health crises could have an adverse impact on our manufacturing capacity, supply chains, and distribution systems as we and other businesses and governments take preventative and precautionary measures designed to slow the spread of COVID-19. We could experience other negative impacts of COVID-19 relating to lack of availability of our key personnel or temporary closures of our office or the facilities of our suppliers or third-party service providers.
The future progression of the COVID-19 pandemic and its resulting impacts on our customers, sales activity, supply chain and distribution networks are highly uncertain at this time. However, the foregoing and other disruptions as a result of COVID-19 could have a material adverse effect on our business, operating results and financial condition, especially to the extent these impacts persist or exacerbate over an extended period of time.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $7.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $23.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $2.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $6.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-07-01 to 2020-09-30 | $5.7m | us-gaap:GrossProfit |
| Gross profit | 9 months2020-01-01 to 2020-09-30 | $17.1m | us-gaap:GrossProfit |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $476.9k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | $784.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-07-01 to 2020-09-30 | −$280.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | −$2.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | $1.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $731.6k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | $0.09 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | $0.09 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 12,493,309 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 12,414,932 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | $3.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $349.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $47.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $62.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $70.4m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $4.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $9.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-09-30 | $60.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-20-122132. Last ingested by Listed: Nov 6, 2026, 03:39 ET. Listed shows no prices and gives no investment advice.